D. Medical signs worldwide marketing deal for insulin-delivery tech

Israel's D. Medical ($DMED) has signed an original equipment manufacturer agreement with Twobiens, a Korean firm, to market its insulin-delivery technology. The deal, worth up to $5 million over three years, will allow Twobiens to commercialize the Spring Universal Infusion Set, which is compatible with most insulin pumps. D. Medical is touting the infusion tech as a major step forward in diabetes treatment, as it can detect when it has been detached from the body and block off its needle, preventing insulin leakage and making for a safer product. The device already carries approval in the U.S., Canada and Europe. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…